HC Wainwright Reiterates "Buy" Rating for Praxis Precision Medicines (NASDAQ:PRAX)

Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research note issued on Friday, Benzinga reports. They presently have a $105.00 price objective on the stock. HC Wainwright’s target price indicates a potential upside of 91.61% from the company’s previous close. PRAX […]

Related Keywords

, Connor Clark Lunn Investment Management Ltd , Nasdaq , Praxis Precision Medicines Inc , Asset Management Inc , Jefferies Financial Group , Silverarc Capital Management , Jump Financial , York Mellon Corp , Praxis Precision Medicines , Get Free Report , Financial Group , Precision Medicines , Praxis Precision , New York Mellon Corp , Management Inc , Capital Management , Connor Clark , Lunn Investment Management , Praxis Precision Medicines Daily ,